Mineralys Therapeutics, Inc.MLYS

Mineralys Therapeutics Inc. is a clinical-stage biopharmaceutical outfit trying to weaponise silence: its lead compound, lorundrostat, is an oral aldosterone synthase inhibitor designed to dial down the hormone that drives stubborn, treatment-resistant hypertension and the downstream cardio-renal-metabolic misery that follows. The company’s public materials describe a pipeline aimed at people whose aldosterone is running in overdrive, a neat story that is still a decade or more away from generating product revenue. (source: Investors, https://ir.mineralystx.com/)

The firm’s most recent 10-Q, filed for the quarter ended 31 March 2026, puts total assets at $652.9 million, of which $112.8 million is cash and equivalents and $638.1 million is shareholders’ equity. Net income attributable to the parent clocked in at a loss of $39.3 million; operating loss was $45.3 million; and cash used in operating activities was $39.5 million. Diluted loss per share was $0.47 on 82.8 million diluted shares. Research and development expense for the quarter was $24.4 million. (source: 10-Q, period ending 2026-03-31, https://www.sec.gov/Archives/edgar/data/1933414/000167265926000036/xslF345X06/wk-form4_1784595624.xml)

In June 2026 the company announced a $150 million underwritten offering of common stock priced at $23.25 per share, with proceeds earmarked for lorundrostat development and general corporate uses, and separately disclosed a $500 million committed debt facility with funds managed by Pharmakon Advisors, LP. A week before that, on 17 July, an insider filed a Rule 144 notice indicating proposed sales of ordinary shares; by 23 July the SEC shows a further Form 4 reflecting share dispositions, underscoring the tension between the capital-markets theatrics and the operating reality of a loss-making biotech still in the clinic. (source: Press Release dated June, https://www.sec.gov/Archives/edgar/data/1933414/000162828026040225/exhibit991-underwriteragre.htm; MLYS 144 (2026-07-21), https://www.sec.gov/Archives/edgar/data/1933414/000196430626000034/xsl144X01/primary_doc.xml)

Mineralys’s product story rests on lorundrostat’s mechanism as a selective aldosterone synthase inhibitor and on a pipeline slide that highlights hypertension first and cardio-renal-metabolic comorbidities thereafter. The company’s materials and team pages project purpose, diversity, and clinical prowess, yet the only line item actually crossing the revenue line in the 10-Q is a zero. (source: Pipeline - Mineralys Therapeutics, https://mineralystx.com/pipeline/; About - Mineralys Therapeutics, https://mineralystx.com/about/)

For investors chasing the promise of a new hypertension drug, the filing trail is still a work in progress. The SEC submissions index shows a steady drumbeat of Forms 4 and 144, while the companyfacts JSON confirms the absence of recognised product revenue in the latest quarterly data. Until lorundrostat-still in active clinical development-generates sales, the business remains a capital-intensive bet on science, not a revenue-generating machine. (source: MLYS SEC EDGAR filing index, https://www.sec.gov/edgar/browse/?CIK=1933414; MLYS SEC companyfacts JSON, https://data.sec.gov/api/xbrl/companyfacts/CIK0001933414.json)